An observational study in Stroke, Ischemic, Thrombectomy and Thrombolytic Therapy, sponsored by Centre Hospitalier de Gonesse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.
Sponsored by Centre Hospitalier de Gonesse · Observational
This study, called TARGET-ASPECT, looks at patients who had a type of stroke called acute ischemic stroke and were treated with clot-busting medicine and a procedure to remove the clot. Even with these treatments, about half of patients don't fully recover. The study aims to see if certain brain imaging scores, especially when combined, can better predict how well patients will recover 90 days after their stroke and if their blood vessels reopen successfully. The study will include 152 patients and last about 9 months. The goal is to find easy and reliable tools that doctors can use to make better treatment decisions.
2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.
This study's planned enrollment of 152 is below the median of 300 across 771 observational studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Centre Hospitalier de Gonesse is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of adult patients (aged 18 and over) who have experienced an acute ischemic stroke confirmed by imaging. These patients have undergone combined treatment with thrombolysis (clot-busting medication) and thrombectomy (mechanical clot removal). They are selected from a single medical center where detailed clinical and imaging follow-up data, including functional outcomes at 90 days, are available. Participants must have adequate-quality imaging and not have experienced early death or loss to follow-up before evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria :
Favorable functional outcome defined as a mRS score of 0 to 2 at 90 days
Time frame: 90 days
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de Gonesse